MTEMQ (Molecular Templates) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTEMQ Molecular Templates Inc MTEMQ
12 GF Score
Price $0.00
View Full Analysis

What is Molecular Templates Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MTEMQ
12GF Score
Molecular Templates Inc MTEMQ
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Templates Business Description

Address 9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc. is a clinical-stage biopharmaceutical company based in the United States that develops engineered toxin bodies (ETBs), a proprietary class of targeted biologic therapeutics for cancer. Its ETB platform uses genetically engineered bacterial toxins that bind to cell-surface targets and are internalized, after which the toxin payload shuts down protein synthesis and kills the target cell. The company's pipeline has included candidates such as MT-0169, targeting CD38 for multiple myeloma and other hematologic cancers, MT-6402, targeting PD-L1, and MT-8421, targeting CTLA-4. These programs are in early-stage clinical development. The company operates as a research and development organization, funding its activities primarily through equity financings, collaboration and licensing arrangements, and grants, and it has no approved products or product revenue. Its activities are conducted mainly in the United States.
12GF Score

Get the complete analysis for MTEMQ

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price